middle.news
NeuroScientific Advances EmtinB Toward Human Trials with A$4.5M Cash Buffer
9:11am on Thursday 30th of January, 2025 AEDT
•
Biopharmaceuticals
Read Story
NeuroScientific Advances EmtinB Toward Human Trials with A$4.5M Cash Buffer
9:11am on Thursday 30th of January, 2025 AEDT
Key Points
Initiation of IND-enabling studies for intravitreal administration of EmtinB
Preliminary melanin binding study informs animal model selection
Planned toxicology and pharmacokinetics studies set for Q2-Q3 2025
Cash balance of A$4.5 million maintained at end of December 2024
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuroscientific Biopharmaceuticals (ASX:NSB)
OPEN ARTICLE